Cyclo Therapeutics, Inc.

NASDAQ (USD): Cyclo Therapeutics, Inc. (CYTH)

Last Price

1.10

Today's Change

+0.33 (42.85%)

Day's Change

0.97 - 1.45

Trading Volume

82,277,078

Profile
CYTH

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. N. Scott Fine Mr. N. Scott Fine

Full Time Employees:  8 8

IPO Date:  2000-05-03 2000-05-03

CIK:  0000922247 0000922247

ISIN:  US23254X2018 US23254X2018

CUSIP:  550241103 550241103

Beta:  -0.38 -0.38

Last Dividend:  0.00 0.00

Dcf Diff:  0.00 0.00

Dcf:  0.00 0.00

Description

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Address

6714 NW 16th Street,
Gainesville, FL 32653, US

386 418 8060

http://www.cyclotherapeutics.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment